PP
CRBU icon

Paladin Partners’s Caribou Biosciences CRBU Stock Holding History

Paladin Partners’s Portfolio CRBU Stock Details CRBU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$88 Hold
50
– – ﹤0.01% 212
2026
Q1 		$95 Hold
50
– – ﹤0.01% 208
2025
Q4 		$80 Buy
+50
New +$105 ﹤0.01% 214

Other funds holding CRBU

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Paladin Partners's CRBU Position: Q2 2026 in Review

Paladin Partners held its Caribou Biosciences (CRBU) position steady in Q2 2026 at 50 shares worth $88. The position accounts for ﹤0.01% of the portfolio, ranked #212.

Paladin Partners first reported a position in CRBU in Q4 2025 and has held it in 3 quarters since. The position peaked at $95 in Q1 2026. 137 funds tracked by Wall St. Rank hold CRBU as of Q2 2026.

  • Paladin Partners held 50 shares of Caribou Biosciences worth $88 as of Q2 2026.
  • Paladin Partners left its Caribou Biosciences share count unchanged in Q2 2026.
  • Caribou Biosciences made up ﹤0.01% of Paladin Partners's portfolio in Q2 2026, its #212 holding.
  • Paladin Partners first reported a position in Caribou Biosciences in Q4 2025 and has held it in 3 quarters since.
  • Paladin Partners's Caribou Biosciences position peaked at $95 in Q1 2026.
  • 137 funds tracked by Wall St. Rank held Caribou Biosciences as of Q2 2026.

Based on Paladin Partners's 13F filing for Q2 2026, filed 7 Aug 2026.